Inclusion Criteria:
- Pretreated metastatic CRPC
- <3 prior systemic treatment regimens or >1 prior regimen in the metastatic setting

Part A
ADXS-PSA Monotherapy
- n=21
- Dose escalation (3 dose levels)

Part B
ADXS-PSA + pembrolizumab
- n=30 (up to 21 in part B, remainder in expansion)
- Dose determination & confirmation

Endpoints:
ADXS-PSA
- Safety
- RP2D

ADXS-PSA
- Safety
- RP2D of the combination

ADXS-PSA
- Pembrolizumab
- Pembrolizumab
- Pembrolizumab

Part B Expansion: Endpoints
- Safety
- Efficacy
- Immunologic Activity

Up to PD or 2 years